ASCERT subanalysis compares procedural costs over long term

11/12/2012 | TCTMD.com

At every point measured, bypass surgery was more expensive than percutaneous coronary intervention, even though CABG demonstrated cost-effectiveness over the longer term, according to a subanalysis of the ASCERT trial reported in the New England Journal of Medicine and discussed at the annual meeting of the American Heart Association. Session co-moderator Dr. Ralph Brindis said many concerns must be taken into account when treatment decisions are made: "As we [care for] the patient, we have to not only think about issues of quality, but accountability, transparency and cost."

View Full Article in:

TCTMD.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ